FOXGLOVES herbal medicine will be on the market by the end of the year, the manufacturer announced Thursday.
The product is designed to provide protection against infections from the fungus Borrelia burgdorferi.
The product will be made by Trevo, a company based in Texas that specializes in producing topical anti-inflammatory medications.
Trevo said the product will provide the same protection as the other treatments, which are sold under the brand name Prolong.
The company said Trevo has obtained FDA approval for its product.
Trevolo said the company has tested the product against Borrelias spores and found it to be safe.
The products were approved for use by the FDA last year for treating respiratory infections caused by the fungus.
Treveo has been making anti-inflammatories since the 1980s.
It was acquired by Pfizer in 2008.
It is not known how many patients Treveo said have received the anti-flagellant.
It did not say how many were using Trevo products.
Pfizer said it was unaware of any adverse reactions from Trevo’s anti-infective treatment products.